New Zealand markets closed

Roivant Sciences Ltd. (ROIV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.25-0.36 (-3.10%)
At close: 04:00PM EDT
11.38 +0.13 (+1.14%)
After hours: 06:39PM EDT

Roivant Sciences Ltd.

50 Broadway
7th Floor
London SW1H 0DB
United Kingdom
44 20 7400 3347

Full-time employees908

Key executives

NameTitlePayExercisedYear born
Mr. Matthew GlineCEO & Director1.77MN/A1984
Dr. Eric Venker M.D., Pharm.D.President & COO1.28MN/A1987
Dr. Mayukh Sukhatme M.D.President, Chief Investment Officer & Director1.72MN/A1976
Mr. Richard PulikChief Financial OfficerN/AN/A1979
Ms. Rakhi KumarChief Accounting OfficerN/AN/A1980
Mr. Drew KramerChief Information OfficerN/AN/AN/A
Mr. Josh ChenGeneral CounselN/AN/AN/A
Ms. Kelly GraffHead of PeopleN/AN/AN/A
Mr. Alex GasnerExecutive Vice President of Roivant HealthN/AN/AN/A
Dr. Matt MaisakChief Operating Officer of Roivant PlatformsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Corporate governance

Roivant Sciences Ltd.’s ISS governance QualityScore as of 1 July 2024 is 9. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.